Skip to main content

Smith & Nephew PLC 6-K, filed Mar 10, 2022

Smith & Nephew PLC (SNN)

6-K 2022-03-10 For: 2022-03-10
View Original
Added on July 04, 2026

About this 6-K

Smith & Nephew PLC filed this 6-K on March 10, 2022.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of

1934

March 09, 2022

Commission File Number 001-14978

SMITH & NEPHEW plc

(Registrant's name)

Building 5, Croxley Park,

Hatters Lane, Watford, Hertfordshire, WD18 8YE,

England

(Address of registrant's principal executive offices)

[Indicate by check mark whether the registrant files or will file annual

reports under cover Form 20-F or Form 40-F.]

Form 20-F X                Form 40-F

---                              ---

[Indicate by check mark if the registrant is submitting the Form 6-K in

paper as permitted by Regulation S-T Rule 101(b)(1).]

Yes                        No X

---             ---

[Indicate by check mark if the registrant is submitting the Form 6-K in

paper as permitted by Regulation S-T Rule 101(b)(7).]

Yes                     No X

---                        ---

[Indicate by check mark whether by furnishing the information contained

in this Form, the registrant is also thereby furnishing information to the

Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of

1934.]

Yes                 No X

---

If "Yes" is marked, indicate below the file number assigned to the

registrant in connection with Rule 12g3-2 (b) : 82- n/a.

SMITH & NEPHEW PLC

9 March 2022

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

1.   VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2010 AND 2020

On 7 March 2022, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") vested under the Smith & Nephew Global Share Plan 2010 and 2020.

i.     FINAL VESTING ON 7 MARCH 2022 OF 2019 EQUITY INCENTIVE PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:

The awards were granted under the Global Share Plan 2010 on 7 March 2019. One third of the Shares vested on 7 March 2020, a further third vested on 7 March 2021 and the final third vested on 7 March 2022. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.

The following relates to individuals included in the below notification:

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted
Description<br>of the financial instrument, type of instrument Smith<br>& Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Final vesting of Equity Incentive Programme awards granted on 7<br>March 2019 under the Smith & Nephew Global Share Plan<br>2010.
Date of Transaction 2022 - 03 - 07
Place of Transaction London Stock Exchange (XLON)
Name<br><br><br>(Position) Status Price (£) Volume Aggregated information Total Ordinary Share Holding following the transaction<br>* Total Ordinary Share Holding as a % of the Company's ISC following<br>the transaction *
--- --- --- --- --- --- ---
Helen Barraclough<br><br><br>(Group General Counsel) PDMR 12.011211 2,417 (of which 1,140 were sold and 1,277 retained) N/A Single Transaction 18,769.75378 ordinary shares 0.00212%
Bradley Cannon<br><br><br>(President, Orthopaedics, Sports Medicine & ENT and<br>Americas) PDMR 12.011211 4,983 (of which 1,688 were sold and 3,295 retained) N/A Single Transaction 81,825.17832 ordinary shares (including 2,718.50860 in<br>ADS') 0.00924%
Phil Cowdy<br><br><br>(Chief Business Development<br>& Corporate Affairs Officer) PDMR 12.011211 2,486 (of which 1,173 were sold and 1,313 retained) N/A Single Transaction 48,446.96621 ordinary shares 0.00547%
Elga Lohler<br><br><br>(Chief HR Officer) PDMR 12.011211 4,724 (of which 1,851 were sold and 2,873 retained) N/A Single Transaction 109,689.00000 ordinary shares (including 3,015.00000 in<br>ADS') 0.01239%
Vasant Padmanabhan<br><br><br>(President Research & Development) PDMR 12.011211 4,274 (of which 1,587 were sold and 2,687 retained) N/A Single Transaction 67307.00000 ordinary shares 0.00760%
Susan Swabey<br><br><br>(Company Secretary) PDMR 12.011211 1,743 (of which 823 were sold and 920 retained) N/A Single Transaction 50,970.39347 ordinary shares 0.00576%

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

ii.   FINAL VESTING ON 7 MARCH 2022 OF SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2019 PERFORMANCE SHARE PROGRAMME AWARDS:

The awards were granted under the Global Share Plan 2020 on 8 March 2021. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards.

The following relates to individuals included in the below notification:

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted
Description<br>of the financial instrument, type of instrument Smith<br>& Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Final vesting on 7 March 2022 of Supplementary Awards granted under<br>the Smith & Nephew Global Share Plan 2020 for the 2019<br>Performance Share Programme awards.
Date of Transaction 2022 - 03 - 07
Place of Transaction London Stock Exchange (XLON)
Name<br><br><br>(Position) Status Price (£) Volume Aggregated information Total Ordinary Share Holding following the transaction<br>* Total Ordinary Share Holding as a % of the Company's ISC following<br>the transaction *
--- --- --- --- --- --- ---
Helen Barraclough<br><br><br>(Group General Counsel) PDMR 12.011211 3,013 (of which 1,422 were sold and 1,591 retained) N/A Single Transaction 20,360.75378 ordinary shares 0.00230%
Bradley Cannon<br><br><br>(President, Orthopaedics, Sports Medicine & ENT and<br>Americas) PDMR 12.011211 7,696 (of which 2,607 were sold and 5,089 retained) N/A Single Transaction 86,914.17832 ordinary shares (including 2,718.50860 in<br>ADS') 0.00982%
Phil Cowdy<br><br><br>(Chief Business Development<br>& Corporate Affairs Officer) PDMR 12.011211 5,641 (of which 2,661 were sold and 2,980 retained) N/A Single Transaction 51,426.96621 ordinary shares 0.00581%
Simon Fraser<br><br><br>(President, Advanced Wound Management & Global Commercial<br>Operations) PDMR 12.011211 6,791 (of which 2,021 were sold and 4,770 retained) N/A Single Transaction 15,433.59428 ordinary shares 0.00174%
Elga Lohler<br><br><br>(Chief HR Officer) PDMR 12.011211 6,680 (of which 2,626 were sold and 4,054 retained) N/A Single Transaction 113,743.00000 ordinary shares (including 3,015.00000 in<br>ADS') 0.01285%
Vasant Padmanabhan<br><br><br>(President Research & Development) PDMR 12.011211 6,595 (of which 2,449 were sold and 4,146 retained) N/A Single Transaction 71,453.00000 ordinary shares 0.00807%
Susan Swabey<br><br><br>(Company Secretary) PDMR 12.011211 2,446 (of which 1,154 were sold and 1,292 retained) N/A Single Transaction 52,262.39347 ordinary shares 0.00590%

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

2.   PHIL COWDY - SALE OF ORDINARY SHARES

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted
Description<br>of the financial instrument, type of instrument Smith<br>& Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Sale of ordinary shares.
Date of Transaction 2022 - 03 - 08
Place of Transaction London Stock Exchange (XLON)
Name (Position) Director / PDMR Price (£) Volume Aggregated information Total Ordinary Share Holding following the transaction<br>* Total Ordinary Share Holding as a % of the Company's ISC following<br>the transaction *
--- --- --- --- --- --- ---
Phil Cowdy<br><br><br>(Chief Business Development<br>& Corporate Affairs Officer) PDMR 11.793781 4,293 N/A Single Transaction 47,133.96621 ordinary shares 0.00532%

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

Sarah Carne

Deputy Company Secretary

Smith & Nephew plc

Tel:  +44 (0)1923 477100

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Smith & Nephew Plc

(Registrant)

Date: March 09, 2022

By: /s/ Susan Swabey


Susan Swabey

Company Secretary